Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Karen K. Ballen et al.|Cancer|2017Cited by 31
A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid LeukemiaAmir T. Fathi, Philip C. Amrein, Traci M. Blonquist et al.|Blood|2016Cited by 4